Gantenerumab + Solanezumab + Matching Placebo (Gantenerumab) + Matching Placebo (Solanezumab) + Gantenerumab + E2814 + Lecanemab + Matching Placebo (E2814)
Phase 2/3Active 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Alzheimers Disease
Conditions
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Trial Timeline
Dec 1, 2012 → Jul 1, 2028
NCT ID
NCT01760005About Gantenerumab + Solanezumab + Matching Placebo (Gantenerumab) + Matching Placebo (Solanezumab) + Gantenerumab + E2814 + Lecanemab + Matching Placebo (E2814)
Gantenerumab + Solanezumab + Matching Placebo (Gantenerumab) + Matching Placebo (Solanezumab) + Gantenerumab + E2814 + Lecanemab + Matching Placebo (E2814) is a phase 2/3 stage product being developed by Eisai for Alzheimers Disease. The current trial status is active. This product is registered under clinical trial identifier NCT01760005. Target conditions include Alzheimers Disease, Dementia, Alzheimers Disease, Familial.
What happened to similar drugs?
0 of 5 similar drugs in Alzheimers Disease were approved
Approved (0) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
15
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01760005 | Phase 2/3 | Active |
Competing Products
15 competing products in Alzheimers Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| E2814 + Lecanemab + Matching Placebo (E2814) | Eisai | Phase 2/3 | 42 |
| Gantenerumab + Solanezumab + Matching Placebo (Gantenerumab) + Matching Placebo (Solanezumab) | Eli Lilly | Phase 2/3 | 38 |
| Remternetug + Matching Placebo (Remternetug) | Eli Lilly | Phase 2/3 | 45 |
| Remternetug (SC) + Matching Placebo (Remternetug) | Eli Lilly | Phase 2/3 | 45 |
| CNP520 50mg + CNP520 15mg | Novartis | Phase 2/3 | 30 |
| CAD106 Immunotherapy + CNP520 | Novartis | Phase 2/3 | 30 |
| Trontinemab | Roche | Phase 3 | 47 |
| RO7126209 + Placebo | Roche | Phase 1 | 29 |
| RO7126209 + Placebo | Roche | Phase 1/2 | 36 |
| Gantenerumab | Roche | Phase 2/3 | 30 |
| Trontinemab | Roche | Phase 3 | 47 |
| Gantenerumab + Placebo | Roche | Phase 3 | 32 |
| Semaglutide + Placebo | Novo Nordisk | Phase 3 | 40 |
| X/T + X-EC + Placebo + Lecanemab 10 mg/kg | Bristol Myers Squibb | Phase 2 | 42 |
| buntanetap/posiphen + Placebo | Annovis Bio | Phase 3 | 37 |